Foundayo Weight Loss Tablets: What They Are & How They Work

Foundayo is a name that has started appearing in a lot of weight loss forums recently, and for good reason. Following its recent MHRA approval, it has become one of the latest prescription weight-loss medicines authorised in the UK, and many people are understandably curious about what it actually is.

This article explains what Foundayo is, how it works, what the evidence says about results, and who it may suit, in plain clinical terms. As a new option in this space, it is worth understanding properly before deciding whether it is relevant to you.

What is Foundayo and how does it work?

Foundayo is an oral prescription weight-loss medicine. Unlike Mounjaro or Wegovy, which are given as a weekly injection, Foundayo is taken as a tablet, once a day.

Its active ingredient is orforglipron, and it is specifically a non-peptide, small-molecule GLP-1 receptor agonist, which is a more precise description than simply calling it "a GLP-1 tablet." This chemistry matters clinically: because it is not a peptide, it does not need the absorption-boosting protocol that peptide-based oral GLP-1 medicines require, so Foundayo can be taken at any time of day, with or without food or water.

In practical terms, it mimics GLP-1, a hormone your gut produces naturally after eating. This signals to the brain that you are full, slows how quickly food leaves the stomach, and helps regulate blood sugar. Combined with a reduced-calorie diet and increased physical activity, this can support meaningful weight loss over time.

As with any prescription-only medicine, Foundayo requires a clinical assessment before it can be prescribed. A clinician needs to confirm it is appropriate for your health history before you can access this oral treatment.

What results can you expect from Foundayo?

In the ATTAIN-1 trial, adults with obesity or overweight (without type 2 diabetes) taking the highest trial dose of Foundayo (36 mg) for 72 weeks lost an average of around 11.2% of their body weight, compared with a much smaller reduction on placebo. [2] In the ATTAIN-2 trial, adults with obesity or overweight and type 2 diabetes lost an average of around 10.5% on the highest dose over the same period, alongside meaningful improvements in blood sugar control. [3]

These figures are averages from clinical trials in which Foundayo was combined with diet and lifestyle changes, not guarantees. Individual results vary considerably depending on adherence, starting weight and lifestyle factors, and realistic weight loss timelines tend to show gradual progress building over many months rather than a rapid transformation.

How does Foundayo compare to Mounjaro, Wegovy or Ozempic?

Administration also differs: Foundayo is a daily tablet, while Mounjaro, Wegovy and Ozempic are weekly injections. Dosing schedules differ between all four and should always be followed according to your specific prescription and clinical guidance rather than assumed. If you are weighing up Mounjaro against Wegovy specifically, our dedicated comparison covers that in more depth.

Is Foundayo available in the UK, and who is eligible?

Foundayo (orforglipron) was authorised by the MHRA on 10 August 2026, making the UK the first country in Europe to approve it, for both weight management and improving blood sugar control in adults with insufficiently controlled type 2 diabetes. [1]

For weight management, Foundayo is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity. [1] It is worth being clear that being licensed in the UK is not the same as being suitable for every individual. Eligibility is assessed using BMI alongside other health and clinical factors, including medical history and any contraindications, rather than BMI in isolation.

At the time of writing, Foundayo is not yet available on the NHS. Lilly has said it plans to launch Foundayo in the UK via private prescription later in August 2026. [8] If you are exploring weight loss options, a consultation can help establish which currently available treatment may be appropriate for you.

What are the side effects of Foundayo?

Foundayo shares a broadly similar side effect profile to other medicines in its class, because it works through the same GLP-1 pathway. The most common side effects are gastrointestinal, and are usually most noticeable in the early weeks or after a dose increase, tending to settle as the body adjusts. [8]

Side effects include:

• Nausea
• Diarrhoea
• Constipation
• Reduced appetite
• Vomiting (in some patients)
• Indigestion (in some patients)
• Abdominal discomfort (in some patients)

There are also rarer but more serious risks that clinicians monitor for, consistent with other GLP-1 receptor agonists. These include acute pancreatitis and, as a class-wide precaution, a warning around thyroid tumours, which is why Foundayo is not suitable for anyone with a personal or family history of certain thyroid cancers. [8]

Foundayo should only ever be taken under medical supervision, with a clinician screening for contraindications beforehand and monitoring your response as treatment continues.

Foundayo and the ATTAIN trial: what does the evidence show for menopausal and perimenopausal women?

Foundayo was studied in the ATTAIN clinical trial programme, and a specific post-hoc analysis looked at how it performed for women at different stages of menopause. This analysis pooled more than 1,500 female participants across the ATTAIN-1 and ATTAIN-2 trials and grouped them by menopausal status: premenopausal, perimenopausal and postmenopausal. [7]

The findings showed statistically significant weight loss across all three groups on the highest dose. In ATTAIN-1, premenopausal, perimenopausal and postmenopausal women lost an average of around 12.8%, 14.4% and 14.1% of their body weight respectively at 72 weeks. In ATTAIN-2, among women with type 2 diabetes, the equivalent figures were around 11.3%, 8.9% and 13.6%. [7] Meaningful reductions in waist circumference were also seen across all groups.

Hormonal changes during perimenopause and menopause can affect weight, appetite and metabolism, often making this a particularly difficult time for weight management, which is relevant context for interpreting these findings. [7] It is also worth noting that this was a post-hoc analysis, conducted by the manufacturer using its own trial data and presented at a scientific conference rather than a pre-specified primary endpoint, so independent research will help build a fuller picture over time.

"At SwiftDoctor, we recognise that weight gain during perimenopause and menopause can have a significant impact on both physical health and quality of life. Where clinically and regulatorily appropriate, we will consider Foundayo treatment for suitable perimenopausal and menopausal women with a BMI of 25 or above. Treatment is never based on BMI alone: every patient is assessed individually, taking into account their medical history, current health, medications, treatment goals and overall risk-benefit profile."

— Dr Saira Bano, GP and Co-Founder of SwiftDoctor

Weight changes during this life stage are common and rarely explained by diet or effort alone. If you are navigating perimenopause symptoms alongside changes in weight, it is worth discussing the full picture with a clinician rather than treating it as a separate issue.

How SwiftDoctor supports patients starting Foundayo

SwiftDoctor clinicians assess suitability individually rather than working from a one-size-fits-all checklist, taking into account your health history, goals and any contraindications before recommending a specific treatment.

Support continues throughout treatment, not just at the point of prescription, with ongoing review built into the service. The approach is judgement-free and personalised, whichever of our weight loss treatments ends up being the right fit for your circumstances.

Frequently asked questions

How effective is Foundayo for weight loss?

In clinical trials, adults taking the highest trial dose of Foundayo lost an average of around 11.2% of their body weight over 72 weeks without type 2 diabetes, and around 10.5% with type 2 diabetes. [2][3] These are trial averages, not guarantees, and individual results depend on adherence, starting weight and lifestyle factors.

Is Foundayo a tablet or an injection?

Foundayo is a tablet, taken once daily by mouth. This is different from Mounjaro, Wegovy and Ozempic, which are all given as a weekly injection under the skin.

Who can take Foundayo?

Foundayo is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related health condition, alongside diet and lifestyle changes. [1] Being licensed does not automatically mean it is suitable for everyone; a clinician assesses eligibility individually, taking your full medical history into account.

How much does Foundayo cost in the UK?

Foundayo is not yet available on the NHS, and a confirmed UK private price has not yet been announced. Lilly has said it plans to launch Foundayo via private prescription later in August 2026. [8] Check current pricing directly with a regulated provider rather than relying on early estimates.

Is Foundayo suitable for perimenopausal or menopausal women?

A post-hoc analysis of the ATTAIN trials found significant weight loss across pre-, peri- and postmenopausal women. [7] Suitability is still assessed individually, taking BMI, health history and clinical factors into account, so this is best discussed directly with a clinician rather than assumed from general trial data.

What happens when you stop taking Foundayo?

Because Foundayo is new, long-term evidence on what happens after stopping treatment is still developing. Experience with other weight-management medicines suggests appetite and weight can change after treatment stops, so it is best to discuss the transition with your clinician and agree how ongoing lifestyle support will be managed.

Sources

1. MHRA / GOV.UK, "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes", gov.uk
2. Wharton, S. et al. (2026). New England Journal of Medicine, "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" (ATTAIN-1), nejm.org
3. Eli Lilly and Company, "Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial" (ATTAIN-2), investor.lilly.com
4. Electronic Medicines Compendium (eMC), "Mounjaro 2.5 mg solution for injection: SmPC" (Eli Lilly), medicines.org.uk
5. Electronic Medicines Compendium (eMC), "Wegovy 0.25 mg–2.4 mg solution for injection: SmPC" (Novo Nordisk), medicines.org.uk
6. Electronic Medicines Compendium (eMC), "Ozempic 0.25 mg solution for injection in pre-filled pen: SmPC" (Novo Nordisk), medicines.org.uk
7. Eli Lilly and Company, "Lilly’s Foundayo (orforglipron)...associated with significant weight loss in women at every stage of menopause", investor.lilly.com
8. U.S. Food and Drug Administration (FDA), "FOUNDAYO (orforglipron) tablets, for oral use: Prescribing Information" (Eli Lilly and Company), fda.gov